The Rilpivirine Cerebrospinal-fluid (CSF) Study

Phase 1

Completed

• Conditions: HIV
• Interventions: Drug: Rilpivirine

• Registration Number: NCT01562886
• Lead Sponsor: Imperial College London

Brief Summary

This is a phase I pharmacokinetic study of HIV positive patients stable on antiretroviral therapy who will switch treatment when enrolled from nevirapine to rilpivirine. On day 60 of the study the participants will attend clinic where they will have blood collected followed by a lumbar puncture where cerebrospinal fluid will be collected to measure drug concentration. The participants will then restart their original regime with nevirapine.

Detailed Description

To investigate the following parameters in HIV-infected patients switching antiretroviral therapy from TDF/FTC/nevirapine to TDF/FTC/rilpivirine for 60 days:

* CSF exposure and CSF : plasma ratio of rilpivirine

* Safety and tolerability of switching antiretroviral therapy from TDF/FTC/nevirapine to TDF/FTC/rilpivirine

* Changes in cerebral metabolites measured via 1-H MRS after switching antiretroviral therapy to TDF/FTC/rilpivirine

* Seminal fluid exposure of rilpivirine

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-03-22
• Study First Submitted QC: 2012-03-23
• Study First Posted: 2012-03-26
• Primary Completion: 2012-11
• Study Completion: 2013-02
• Status Verified: 2014-05
• Results First Submitted: 2014-05-19
• Results First Submitted QC: 2014-05-19
• Last Update Submitted: 2014-05-19
• Results First Posted: 2014-06-19
• Last Update Posted: 2014-06-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 14

Inclusion Criteria

• HIV-1 infected males subjects
• signed informed consent
• willing to switch therapy as per study protocol
• no previous exposure to rilpivirine
• plasma HIV RNA < 50 copies/mL at screening and on at least one other occasion over the last 3 months
• currently receiving a stable antiretroviral regimen comprising of TDF/FTC with nevirapine with nevirapine dosed either 200 mg twice daily or 400 mg once daily with no antiretroviral drug switches for at least 3 months
• no clinically-significant resistance documented on any prior HIV-1 genotypic resistance testing
• subjects in good health upon medical history, physical exam, and laboratory testing
• BMI above or equal to 18 and below 32
• Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom and diaphragm) during heterosexual intercourse, from screening through completion of the study.
• Have local screening laboratory results (haematology and chemistry that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance
• No contraindications to having a lumbar puncture examination found on MRI of the brain

Exclusion Criteria

• current alcohol abuse or drug dependence
• positive urine drug of abuse screening
• active opportunistic infection or significant co-morbidities
• current disallowed concomitant medication (as listed in section 4.1.3)
• contraindication to MR examination or lumbar puncture examination
• recent head injury (in last 30 days) or chronic ongoing neurological diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Rilpivirine and Truvada	Rilpivirine	TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily

Primary Outcome Measures

Name	Time	Method
CSF:Plasma Ratio of Rilpivirine Levels	Day 60	The levels of rilpivirine will be measured in the cerebral spinal fluid and plasma after 60 days of exposure

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With HIV Viral Load Above 50 Copies Per mL	Day 3,14, 28, 60, 80-100	Plasma viral load will be measured at all study visits to assess if viral load is above the lower limit of detection (50 copies mL)

Trial Locations

Locations (1)

Imperial College Healthcare NHS Trust; 🇬🇧 London, United Kingdom